FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016036456> ?p ?o ?g. }

• W2016036456 endingPage "3575" @default.
• W2016036456 startingPage "3574" @default.
• W2016036456 abstract "Infectious diseases caused by pathogenic bacteria have been the leading cause of morbidity and mortality in human history. The discovery of the antibacterial compound from the mold Penicillium notatum by Alexander Fleming led to the development of antibiotics, which are still the main weapons for combating the deadly bacterial infections at the present time. However, over 60 years of application of antibiotics leads to the development of antibiotic resistance of many bacterial pathogens. Consequently, bacterial infections have again become the most common and deadly causes of human diseases. Two of the most lethal hospital infections are caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) (10). Furthermore, Streptococcus mutans-associated tooth decay is one of the most prevalent and costly infectious diseases in the United States (4, 11; http://www.surgeongeneral.gov/library/oralhealth/).The emergence of both “new pathogens” and resistant strains from “old pathogens” demands new antibacterial compounds to deal with this crisis. Given the fact that most commonly used antibiotics are isolated from microorganisms, it is important to search for new antibacterial compounds from new bio-resources. Chinese medicinal herbs are logical choices due to their proven ability to treat microbial infections. In traditional Chinese medicine (TCM) practice, a group of herbs has been widely used for a specific therapeutic application defined as Qing Re Jie Du (), or “alleviating heat and relieving the symptoms caused by toxins” (2, 3). Many herbs in this category have been found to have antimicrobial activities (2, 3). Recently, we conducted a systematic screen of herbs with Qing Re Jie Du function for the inhibitory activities against S. mutans, the primary etiological agent for dental caries and other pathogens (1), and found that the extract made from Sophora flavescens contains a potent bioactivity against S. mutans, MRSA, and VRE.S. flavescens is a perennial shrub found in Northeast Asia (Fig. ​(Fig.1A).1A). It grows in sandy soils on mountain slopes or river valleys. In spring or autumn, the roots are collected, cleaned, sliced, and air-dried. The processed root of S. flavescens is also known as “Ku Shen,” which means “a precious medicinal root with bitter taste” (Fig. ​(Fig.1B).1B). In more than 1,000 years of TCM practice, it has being used to treat pyretic and analgesic symptoms (http://www.itmonline.org/arts/sophora.htm). Although a variety of bioactive compounds have been recently isolated from S. flavescens for the treatment of inflammation, cancer, and cardiovascular disorders (5, 13), the knowledge about its antibacterial potential is limited (7).FIG. 1.Sophora flavescens (A) and its dried roots (Ku Shen) (B) used in TCM application.To study the active antimicrobial component(s) in S. flavescens, the following procedures were followed. First, an extract of S. flavescens was prepared according to a previously published extraction method (1), and its MIC against S. mutans was determined with a protocol recommended by the National Committee of Clinical Laboratory Standards (NCCLS) (9) (Table ​(Table1).1). Following the bioassay, the extract was then chromatographed over silica gel (100- to 200-mesh; Selecto, Georgia), and eluted with a hexane:ethyl gradient acetate. Equal volumes of the eluted solutions were collected, dried by evaporation, and subjected to the antimicrobial assay to track down the most active fraction(s). Following the bioassay, the chemical composition of active fractions was then analyzed by thin-layer chromatography and high-performance liquid chromatography (HPLC). The result indicated that the most active fraction contains ∼80% of the active compound. Further purification was performed on semipreparative HPLC equipment (600E system controller and 996 photodiode array detector; Waters, Milford, MA) equipped with a reverse-phase C18 column (7.8 by 300 mm). The homogeneity of the purified active compound (>95%) was established by both HPLC profiles (data not shown) and subsequent 1H nuclear magnetic resonance (NMR) spectra (500 MHz) (Fig. ​(Fig.22).FIG. 2.Proton-NMR spectrum of purified kurarinone.TABLE 1.Susceptibility of S. mutans, MRSA, and VRE to antimicrobial compounds and kurarinoneThe purified compound was then analyzed by mass spectrometer and NMR spectroscopy (1H and 13C), respectively. Based on the extensive one- and two-dimensional (1D and 2D)NMR spectroscopic interpretation and mass spectrometer analysis (data not shown), we concluded that the isolated active compound is kurarinone, a known compound isolated from S. flavescens (5, 7, 8, 13). Kurarinone is a flavonoid with a lavandulyl side chain, and its chemical structure is illustrated in Fig. ​Fig.33.FIG. 3.Kurarinone (A) and its time- and dose-dependent bactericidal effect against S. mutans (B). The chemical structure of kurarinone was elucidated on the basis of extensive 1D and 2D NMR spectroscopic interpretation. The killing effect of kurarinone was determined ...Several bioactivities of kurarinone have been previously reported, including antifungal activities against Candida albicans and Cladosporium cucumerinum(12), antimalarial activity (6), cytotoxic activity against human tumor cells (myeloid leukemia HL-60 cells) (5), and COX-1 inhibitory activity (5). At the current stage, the molecular mechanisms of its action in both pathogens and mammalian cells are largely unknown. In this study, a strong antibacterial activity of kurarinone was detected. Its MICs against S. mutans and multidrug-resistant strains (MRSA and VRE) are at the same level (2 μg/ml) (Table ​(Table1).1). Time- and dose-dependent bactericidal effects of kurarinone against S. mutans (Fig. ​(Fig.3B),3B), MRSA, and VRE (data not shown) were also detected. These data suggested a potential application of kurarinone for the treatment of diseases or conditions associated with S. mutans, MRSA, and VRE." @default.
• W2016036456 created "2016-06-24" @default.
• W2016036456 creator A5008524910 @default.
• W2016036456 creator A5013395521 @default.
• W2016036456 creator A5016547254 @default.
• W2016036456 creator A5037989560 @default.
• W2016036456 creator A5043743788 @default.
• W2016036456 creator A5061441266 @default.
• W2016036456 creator A5078000842 @default.
• W2016036456 date "2005-07-01" @default.
• W2016036456 modified "2023-09-27" @default.
• W2016036456 title "Inhibition of Growth of <i>Streptococcus mutans</i> , Methicillin-Resistant <i>Staphylococcus aureus</i> , and Vancomycin-Resistant Enterococci by Kurarinone, a Bioactive Flavonoid Isolated from <i>Sophora flavescens</i>" @default.
• W2016036456 cites W1975120319 @default.
• W2016036456 cites W2029958298 @default.
• W2016036456 cites W2075515608 @default.
• W2016036456 cites W2086245267 @default.
• W2016036456 cites W2123347870 @default.
• W2016036456 cites W2162939211 @default.
• W2016036456 cites W4295749830 @default.
• W2016036456 doi "https://doi.org/10.1128/jcm.43.7.3574-3575.2005" @default.
• W2016036456 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1169149" @default.
• W2016036456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16000511" @default.
• W2016036456 hasPublicationYear "2005" @default.
• W2016036456 type Work @default.
• W2016036456 sameAs 2016036456 @default.
• W2016036456 citedByCount "47" @default.
• W2016036456 countsByYear W20160364562012 @default.
• W2016036456 countsByYear W20160364562013 @default.
• W2016036456 countsByYear W20160364562014 @default.
• W2016036456 countsByYear W20160364562015 @default.
• W2016036456 countsByYear W20160364562017 @default.
• W2016036456 countsByYear W20160364562018 @default.
• W2016036456 countsByYear W20160364562019 @default.
• W2016036456 countsByYear W20160364562020 @default.
• W2016036456 countsByYear W20160364562021 @default.
• W2016036456 countsByYear W20160364562022 @default.
• W2016036456 countsByYear W20160364562023 @default.
• W2016036456 crossrefType "journal-article" @default.
• W2016036456 hasAuthorship W2016036456A5008524910 @default.
• W2016036456 hasAuthorship W2016036456A5013395521 @default.
• W2016036456 hasAuthorship W2016036456A5016547254 @default.
• W2016036456 hasAuthorship W2016036456A5037989560 @default.
• W2016036456 hasAuthorship W2016036456A5043743788 @default.
• W2016036456 hasAuthorship W2016036456A5061441266 @default.
• W2016036456 hasAuthorship W2016036456A5078000842 @default.
• W2016036456 hasBestOaLocation W20160364561 @default.
• W2016036456 hasConcept C142724271 @default.
• W2016036456 hasConcept C169760540 @default.
• W2016036456 hasConcept C188947578 @default.
• W2016036456 hasConcept C204787440 @default.
• W2016036456 hasConcept C2775965595 @default.
• W2016036456 hasConcept C2776545273 @default.
• W2016036456 hasConcept C2776625710 @default.
• W2016036456 hasConcept C2777052132 @default.
• W2016036456 hasConcept C2778430296 @default.
• W2016036456 hasConcept C2778484605 @default.
• W2016036456 hasConcept C2778980435 @default.
• W2016036456 hasConcept C2779288629 @default.
• W2016036456 hasConcept C2779489039 @default.
• W2016036456 hasConcept C2910137292 @default.
• W2016036456 hasConcept C3019249092 @default.
• W2016036456 hasConcept C501593827 @default.
• W2016036456 hasConcept C523546767 @default.
• W2016036456 hasConcept C54355233 @default.
• W2016036456 hasConcept C71924100 @default.
• W2016036456 hasConcept C86803240 @default.
• W2016036456 hasConcept C89423630 @default.
• W2016036456 hasConceptScore W2016036456C142724271 @default.
• W2016036456 hasConceptScore W2016036456C169760540 @default.
• W2016036456 hasConceptScore W2016036456C188947578 @default.
• W2016036456 hasConceptScore W2016036456C204787440 @default.
• W2016036456 hasConceptScore W2016036456C2775965595 @default.
• W2016036456 hasConceptScore W2016036456C2776545273 @default.
• W2016036456 hasConceptScore W2016036456C2776625710 @default.
• W2016036456 hasConceptScore W2016036456C2777052132 @default.
• W2016036456 hasConceptScore W2016036456C2778430296 @default.
• W2016036456 hasConceptScore W2016036456C2778484605 @default.
• W2016036456 hasConceptScore W2016036456C2778980435 @default.
• W2016036456 hasConceptScore W2016036456C2779288629 @default.
• W2016036456 hasConceptScore W2016036456C2779489039 @default.
• W2016036456 hasConceptScore W2016036456C2910137292 @default.
• W2016036456 hasConceptScore W2016036456C3019249092 @default.
• W2016036456 hasConceptScore W2016036456C501593827 @default.
• W2016036456 hasConceptScore W2016036456C523546767 @default.
• W2016036456 hasConceptScore W2016036456C54355233 @default.
• W2016036456 hasConceptScore W2016036456C71924100 @default.
• W2016036456 hasConceptScore W2016036456C86803240 @default.
• W2016036456 hasConceptScore W2016036456C89423630 @default.
• W2016036456 hasIssue "7" @default.
• W2016036456 hasLocation W20160364561 @default.
• W2016036456 hasLocation W20160364562 @default.
• W2016036456 hasLocation W20160364563 @default.
• W2016036456 hasLocation W20160364564 @default.
• W2016036456 hasOpenAccess W2016036456 @default.
• W2016036456 hasPrimaryLocation W20160364561 @default.
• W2016036456 hasRelatedWork W1552806856 @default.
• W2016036456 hasRelatedWork W1969129407 @default.
• W2016036456 hasRelatedWork W2016036456 @default.

• next